Home > Oncology > No benefit to adding radiation to PD-L1/CTLA-4 therapy in resistant metastatic NSCLC

No benefit to adding radiation to PD-L1/CTLA-4 therapy in resistant metastatic NSCLC


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Oncology
Reuters Health - 25/01/2022 - In patients with resistant metastatic non-small-cell lung cancer (NSCLC), adding radiation to PD-L1 and CTLA-4 inhibition alone or combination did not increase responses, researchers say.  However, the findings suggest that combination PD-L1 plus CTLA-4 might be an option on its own for such patients, note Dr. Jonathan Schoenfeld of Dana-Farber Cancer Institute in Boston and colleagues in The Lancet Oncology.  "Patients with higher numbers of infiltrating T-cell populations that expressed the PD-1 receptor at baseline were more likely to respond to treatment.," Dr. Schoenfeld told Reuters Health by email.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on